Pharmacyclics, J&J's Janssen Now Confirming FDA Approval of IMBRUVICA

Pharmacyclics, Inc. (NASDAQ: PCYC ) today announced that the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA™ (ibrutinib) as a single agent for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.1 This indication is based on overall response rate